Abstract | OBJECTIVE: PATIENTS: In this report, 5 prepubertal children (aged 3.5-10.9 years) with well-controlled HR on conventional therapy were given adjunctive standard dose rhGH therapy for one year. DESIGN AND MEASUREMENTS: Height, growth velocity, metabolic markers of calcium and phosphate metabolism, body composition, bone mineral density, wrist and knee X-rays, and renal sonography were assessed at regular intervals. Height and growth velocities were also calculated 12 months after ceasing rhGH therapy. RESULTS: After 12 months therapy with rhGH, no significant biochemical or radiological benefits were observed. A significant increase in height SD score was observed (P = 0.023), but this was not associated with any increase in the growth velocity SD score and appears to have been due to catch-up growth caused by conventional therapy alone. When rhGH therapy was ceased, no significant decreases in mean height SD or growth velocity SD scores were observed. CONCLUSIONS: In well-controlled hypophosphataemic rickets patients receiving conventional therapy, adjunctive therapy with standard dose rhGH offers no benefits in linear growth or rachitic disease markers.
|
Authors | F J Cameron, E B Sochett, A Daneman, S W Kooh |
Journal | Clinical endocrinology
(Clin Endocrinol (Oxf))
Vol. 50
Issue 5
Pg. 577-82
(May 1999)
ISSN: 0300-0664 [Print] England |
PMID | 10468922
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Phosphates
- Growth Hormone
- Calcitriol
|
Topics |
- Body Composition
(drug effects)
- Body Height
(drug effects)
- Bone Density
(drug effects)
- Calcitriol
(therapeutic use)
- Child
- Child, Preschool
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Growth Hormone
(therapeutic use)
- Humans
- Hypophosphatemia, Familial
(drug therapy, metabolism, physiopathology)
- Male
- Phosphates
(metabolism, therapeutic use)
|